StocksMedium•4 October 2026•
1 min read
CSL Signs $1.6 Billion Rare Disease Drug Deal with Alentis
Key Facts
1Australia's CSL entered an agreement with Swiss-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases.
2The deal is valued at up to $1.6 billion before development funding is taken into account.
Australia's CSL entered an agreement with Swiss-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases. Reuters reported that the deal is valued at up to $1.6 billion before development funding is taken into account.
The partnership aims to expand CSL's portfolio in the rare disease sector by leveraging Alentis's therapeutic pipeline. This strategic move strengthens the company's position in specialized medicine, with the final deal value contingent on reaching specific development milestones.